|Bid||311.15 x 1100|
|Ask||312.06 x 1400|
|Day's Range||311.26 - 323.24|
|52 Week Range||212.66 - 382.15|
|Beta (5Y Monthly)||0.85|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||339.31|
An experimental drug developed by argenx SE led to improvements in daily activities, including chewing and swallowing, in patients suffering from a muscle-weakening autoimmune disease, according to data published in the Lancet Neurology medical journal on Wednesday. The late-stage study met its main goal of demonstrating that a greater percentage of patients on the treatment showed improvement in their daily activities compared to those on placebo. The study enrolled 167 participants to evaluate argenx's lead drug, efgartigimod, which seeks to reduce a type of disease-causing antibodies commonly found in patients with the chronic, rare autoimmune disorder called generalized myasthenia gravis.
Results from ADAPT showed treatment with efgartigimod provided clinically meaningful improvements in strength and quality of life measures in generalized myasthenia gravis (gMG) Efgartigimod is under U.S. Food and Drug Administration (FDA) review with December 17, 2021 Prescription Drug User Fee Act (PDUFA) target action date Breda, the Netherlands —Jun. 16, 2021— argenx (Euronext & Nasdaq: ARGX), today announced that The Lancet Neurology has published pivotal trial results from the Phase 3 ADAP
The company's main selling point is a drug called efgartigimod, which the company is testing in six different diseases.